A practical reference on GHRH analog: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-07-04. Anything still debated is marked as such rather than presented as settled.
Metabolic interest in this compound centers on fat distribution rather than on hormone levels alone. Imaging trials in adults with excess abdominal fat report reductions in visceral adipose tissue, while subcutaneous depots change comparatively little. Growth hormone and IGF-1 are presumed to carry the effect, but the separate contribution of each is not firmly established. Whether these changes persist after treatment stops, and whether they alter longer-term health outcomes, remain open questions that published work does not answer consistently.
Tesamorelin is a synthetic peptide of forty-four amino acids whose sequence reproduces human growth hormone-releasing hormone. Its distinguishing feature sits at the amino terminus, where a trans-3-hexenoyl group replaces the free amine. That acylation slows cleavage by dipeptidyl peptidase IV, an enzyme that otherwise removes the first two residues and inactivates the natural hormone quickly. The modified peptide therefore persists longer in circulation while keeping the same receptor target. It is handled as a lyophilized solid and dissolved shortly before use.
Signaling begins at the GHRH receptor, a class B G protein-coupled receptor displayed on somatotroph cells of the anterior pituitary. Receptor occupancy activates Gs proteins, which raise adenylyl cyclase activity and intracellular cyclic AMP, in turn driving protein kinase A dependent pathways. The downstream output is synthesis and pulsatile secretion of growth hormone into the bloodstream. Hepatic tissue and peripheral sites respond by increasing insulin-like growth factor 1 production. Somatostatin and IGF-1 itself supply negative feedback that caps the size and duration of each secretory burst.
A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic 44-residue peptide | GHRH analog backbone |
| Approximate molecular mass | 5136 Da | Varies with counterion and hydration state |
| N-terminal group | trans-3-hexenoyl | Increases resistance to dipeptidyl peptidase IV |
| Primary receptor | GHRH receptor (GHRHR) | Class B G protein-coupled receptor on somatotrophs |
| Principal mediator | IGF-1 | Rises indirectly after growth hormone release |
The hexenoyl cap slows the enzyme step that trims the amino terminus of native GHRH, the same step that shortens its active lifetime in circulation. As a result, the modified peptide persists longer in plasma than the unmodified hormone in side-by-side comparison. Receptor activity stays broadly comparable, because the added group sits away from the residues that contact the binding site. This combination, preserved receptor activity with reduced degradation, explains why the analog was developed instead of the native sequence.
Several compounds share the GHRH framework, including sermorelin, the shorter 1-29 fragment, and other analogs built on the full 1-44 chain. Naming follows a common convention: a stem that identifies the peptide plus a suffix marking analog status. Reports may describe tesamorelin by its sequence fragment, as a GHRH(1-44) analog, or by its amino-terminal modification. Indexing the compound therefore requires searching all of these forms, since some older literature predates the current international nonproprietary name.
Tesamorelin is a synthetic peptide built from 44 amino acids and classified with the growth hormone–releasing hormone family. Its sequence corresponds to the human GHRH(1-44) backbone, carrying one structural change at the amino terminus. That change is a trans-3-hexenoyl group placed where the natural peptide would have an unmodified end. The modification is the feature that separates the compound from the endogenous hormone in name, in stability, and in how it is handled in the laboratory.
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
Opposing Force received mainly positive reviews, holding a score of 85.45% on the review aggregator site GameRankings. In the United States, the game sold 108,008 copies by the end of 1999. Although figures for sales on Steam have not been released, Opposing Force eventually sold over 1.1 million copies at retail. Computer and Video Games reviewer Kim Randell noted that "Gearbox has obviously gone to great pains to provide a similar experience to the original". Praise was also given to the multiplayer; Randell stated that the new additions for multiplayer made it the area of Opposing Force that "really shines". Randell closed the review by concluding that Opposing Force is "an awesome achievement". Erik Wolpaw, writing for GameSpot, noted that as most expansion packs were mediocre, "it's appropriate that Gearbox Software's Opposing Force, the official expansion for the genre-redefining Half-Life, in turn sets a new standard of quality for future action-game mission packs". Wolpaw praised the design of the single-player campaign, commenting that "you can sense the designers' enthusiasm as one memorable scene unfolds after another, and it compels you to keep playing". Although criticizing some elements of the artificial intelligence and describing some of the new models as "merely window dressing", the review concluded that Opposing Force was an "impassioned application of creative design".
The main steroid hormones, testosterone, estradiol, and progesterone as well as prolactin play important physiological functions in puberty. The production of gonadal steroids in females starts with production of testosterone, which is typically quickly converted to estradiol inside the ovaries. However the rate of conversion from testosterone to estradiol (driven by FSH/LH balance) during early puberty is highly individual, resulting in very diverse development patterns of secondary sexual characteristics. Production of progesterone in the ovaries begins with the development of ovulatory cycles in females (during the lutheal phase of the cycle), before puberty low levels of progesterone are produced in the adrenal glands of both males and females. Estradiol levels rise earlier and reach higher levels in women than in men. While estradiol promotes growth of the breasts and uterus, it is also the principal hormone driving the pubertal growth spurt and epiphyseal maturation and closure.
The country restored its independence in 1813 and recalled William V's son, William Frederick, from exile; he formally established the modern Kingdom of the Netherlands in 1815 as King William I, and securing the dynastic continuity of the House of Orange-Nassau that extends to the reigning monarch today, Willem Alexander.
Copper(II) salts have an LD50 of 100 mg/kg. Copper(II) sulfate was used in the past as an emetic. It is now considered too toxic for this use. It is still listed as an antidote in the World Health Organization's Anatomical Therapeutic Chemical Classification System.
==== Hypothetical origin ==== The top half of tRNA (consisting of the T arm and the acceptor stem with 5′-terminal phosphate group and 3′-terminal CCA group) and the bottom half (consisting of the D arm and the anticodon arm) are independent units in structure as well as in function. The top half may have evolved first including the 3′-terminal genomic tag which originally may have marked tRNA-like molecules for replication in early RNA world. The bottom half may have evolved later as an expansion, e.g. as protein synthesis started in RNA world and turned it into a ribonucleoprotein world (RNP world). This proposed scenario is called genomic tag hypothesis. In fact, tRNA and tRNA-like aggregates have an important catalytic influence (i.e., as ribozymes) on replication still today. These roles may be regarded as 'molecular (or chemical) fossils' of RNA world. In March 2021, researchers reported evidence suggesting that an early form of transfer RNA could have been a replicator ribozyme molecule in the very early development of life, or abiogenesis. Evolution of type I and type II tRNAs is explained to the last nucleotide by the three 31 nucleotide minihelix tRNA evolution theorem, which also describes the pre-life to life transition on Earth. Three 31 nucleotide minihelices of known sequence were ligated in pre-life to generate a 93 nucleotide tRNA precursor.
Sources: en.wikipedia.org
=== Act 2 === Lucinda, a runaway slave, rifles through the pockets of the dead chain gang prisoners. Inman regains consciousness and awakens, which startles her. Lucinda frees Inman, who resumes his journey. Back at Black Cove Farm, Stobrod and his traveling companion Pangle still rely upon Ruby and Ada for sustenance. Stobrod tries to convince Ruby that he is a changed man, but Ruby remains skeptical. Inman meets Sara, a war widow, who is trying to comfort her baby. Inman helps her, gains her trust, and is invited to spend the night. At Black Cove Farm, Teague appears, with a copy of the newspaper that lists the names of deserters, on which Ruby sees her father's name. The next morning, Inman and Sara react quickly when Union soldiers appear. At a campfire in the woods, Teague and his men confront Stobrod and Pangle, shoot them and leave them for dead. Ada finds the two men, and expresses compassion for Stobrod ("I feel sorry for you"). Ada later goes hunting in the woods. There, she and Inman reunite. The other characters whom Inman has encountered on his odyssey appear to Inman, and urge him to tell Ada about his adventures ("Tell her of the slave you met"; "Tell her how the boat went down"). The couple affirms their pledge to each other. Teague continues his pursuit. Ada and Inman consummate their love, on their final night together. Eventually, Teague and the Home Guard track down Inman. In the final battle, Inman is killed.
=== Warm temperature plants === These plants prefer to grow at temperatures of 18 °C (65 °F) to 30 °C (86 °F) Others – Begonia, Ylang Ylang – Cananga odorata, Cooktown Orchid – Dendrobium bigibbum, Tasmanian Blue Gum – Eucalyptus globulus, Poinsettia – Euphorbia pulcherima, Gladiolus – Gladiolus, Gumamela – Hibiscus rosa-sinensis, Busy Lizzie – Impatiens, Lobelia – Lobelia cardinalis, Oleander – Nerium oleander, Frangipani – Plumeria rubra, Petunia, Sampaguita – Jasminum sambac, Sturt's Desert Rose – Gossypium sturtianum, Waratah – Telopia specisissima, Royal Bluebell – Wahlenbergia gloriosa
To gain regulatory approval, the milbemycin oxime/lufenuron heartworm treatment was divested to Virbac. In March 2015, the company announced it would join Hanmi Pharmaceutical in developing and commercializing Hanmi's phase I Bruton's tyrosine kinase inhibitor HM71224 in a deal that could yield $690 million. A day later, however, the company announced another deal with China's Innovent Biologics to co-develop and commercialize at least three of Innovent's treatments over the next decade, in a deal which could generate up to $456 million; the collaboration was subsequently expanded in 2022, according to Innovent. As part of the deal, the company contributed its c-Met monoclonal antibody, and Innovent contributed a monoclonal antibody, which targets CD-20. The second compound from Innovent is a preclinical immunooncology molecule. The following week, the company announced it would restart its collaboration with Pfizer surrounding the Phase III trial of Tanezumab. Pfizer is expected to receive an upfront sum of $200 million from the company. In April 2015, Lilly engaged CBRE Group to sell its biomanufacturing facility in Vacaville, California, a 52 acres (0.21 km2) campus and facility that is one of the largest biopharmaceutical manufacturing centers in the US. In July 2016, Lechleiter retired and was succeeded by David Ricks. In January 2017, Elanco, at the time a subsidiary of Lilly, acquired Boehringer Ingelheim Vetmedica, a subsidiary of Boehringer Ingelheim's US feline, canine, and rabies vaccines portfolio, for $885 million.
== Function == EGF, via binding to its cognate receptor, results in cellular proliferation, differentiation, and survival. Salivary EGF, which seems to be regulated by dietary inorganic iodine, also plays an important physiological role in the maintenance of oro-esophageal and gastric tissue integrity. The biological effects of salivary EGF include healing of oral and gastroesophageal ulcers, inhibition of gastric acid secretion, stimulation of DNA synthesis as well as mucosal protection from intraluminal injurious factors such as gastric acid, bile acids, pepsin, and trypsin and to physical, chemical and bacterial agents.
Sources: en.wikipedia.org
== Growth == The optimal growth temperature range for B. cereus is 30–40 °C (86–104 °F). At 30 °C , a population of B. cereus can double in as little as 20 minutes or as long as 3 hours, depending on the food product. Spores of B. cereus are not metabolically active, but can rapidly become active and begin replicating once they encounter adequate growth conditions.
=== Abuse potential === Pregabalin has potential for recreational use and abuse. It possesses a relatively wide therapeutic index and margin of safety compared to other central nervous system (CNS) depressants, and its effects may include euphoria, anxiolysis, and sedation. Although generally considered to have low abuse potential, reports describe pregabalin inducing sensations of euphoria, calmness, excitement, and a "high" comparable to that of cannabis. These effects may contribute to the development of substance dependence, and withdrawal symptoms can occur if the medication is stopped abruptly. While pregabalin and cannabis share certain effects, such as CNS depressant and orexigenic (appetite-stimulating) properties, they differ significantly in their pharmacodynamics. Cannabis is primarily an anxiogenic substance with mild psychedelic effects, whereas pregabalin is an anxiolytic agent associated with mild euphoria that is prone to rapid tolerance.
The current supply is based on a semisynthetic process developed by PharmaMar starting from safracin B, a chemical obtained by fermentation of the bacterium Pseudomonas fluorescens. PharmaMar entered into an agreement with Johnson & Johnson to market the compound outside Europe.
== Uses == Peroxydisulfuryl difluoride can be used to produce fluorosulfates. It is a strong oxidizing agent and can be used for the oxidation of noble metals (Ag Au Re Pt Os Rh) to the salts of fluorosulfuric acid.
Colonial: small, regular groups of motile cells Capsoid: individual non-motile cells embedded in mucilage Coccoid: individual non-motile cells with cell walls Palmelloid: nonmotile cells embedded in mucilage Filamentous: a string of connected nonmotile cells, sometimes branching Parenchymatous: cells forming a thallus with partial differentiation of tissues In three lines, even higher levels of organization have been reached, with full tissue differentiation. These are the brown algae,—some of which may reach 50 m in length (kelps)—the red algae, and the green algae. The most complex forms are found among the charophyte algae (see Charales and Charophyta), in a lineage that eventually led to the higher land plants. The innovation that defines these nonalgal plants is the presence of female reproductive organs with protective cell layers that protect the zygote and developing embryo. Hence, the land plants are referred to as the Embryophytes.
Sources: en.wikipedia.org
The amino acid sequence matches human growth hormone-releasing hormone, but the amino terminus carries a trans-3-hexenoyl group instead of a free amine. That single structural change chiefly affects enzymatic stability rather than receptor selectivity.
Growth hormone released from the pituitary stimulates IGF-1 production in the liver and other tissues, so circulating IGF-1 generally rises during exposure. The size of the rise varies between individuals and depends on baseline hormonal status and other concurrent factors.
Reported imaging studies focus on visceral adipose tissue, where reductions are more consistently observed across trials. Subcutaneous depots show smaller and less reproducible changes, so the two compartments should not be treated as equivalent.
It is a synthetic peptide analog of human growth hormone-releasing hormone. It is used clinically to reduce excess visceral abdominal fat in adults with HIV-associated lipodystrophy. It works by stimulating pituitary growth hormone release.